---
title: "Bismuth-Containing Quadruple Therapy vs Metronidazole Triple Therapy for Clarithromycin-Resistant"
id: "pubmed-42740438"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42740438"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42740438/"
doi: "10.5009/gnl250435"
published_at: "2026-09-15T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Bismuth-Containing Quadruple Therapy vs Metronidazole Triple Therapy for Clarithromycin-Resistant
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42740438
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42740438/)
- **DOI:** [10.5009/gnl250435](https://doi.org/10.5009%2Fgnl250435)
- **Published At:** 2026-09-15T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- This multicenter randomized controlled trial compared three 14-day regimens for **clarithromycin-resistant Helicobacter pylori**: PPI + amoxicillin + metronidazole (PAM), PAM plus bismuth (PAM-B), and PPI + bismuth + metronidazole + tetracycline (PBMT). - Study enrolled patients with clarithromycin-resistant H. pylori in Busan and Gyeongsangnam-do, Republic of Korea, between December 2022 and February 2024. - In the intention-to-treat (ITT) analysis, eradication rates were: PAM 68.2%, PAM-B 84.8% (PAM vs PAM-B p=0.024), PBMT 81.8% (difference PAM vs PBMT not significant, p=0.070). - In the per-protocol (PP) analysis, eradication rates were: PAM 75.4%, PAM-B 96.5% (PAM vs PAM-B p=0.001), PBMT 94.6% (PAM vs PBMT p=0.004). - Eradication rates were comparable between PAM-B and PBMT in both ITT (p=0.640) and PP analyses (p=0.633). - Adverse events were generally uncommon and reversible after stopping therapy; **nausea and vomiting** occurred significantly less often with PAM-B than with PBMT (6.8% vs 25.0%; p=0.007). - Severe adverse events were rare; all reported symptoms resolved after discontinuation. - Authors conclude PAM-B produced higher eradication rates than PAM and rates comparable to PBMT without a significant increase in adverse events, suggesting PAM-B may be a potential first-line option for clarithromycin-resistant H. pylori. Further large-scale validation is recommended. - The trial was registered retrospectively with the Clinical Research Information Service (CRIS; KCT0012265). Details such as total patient numbers, baseline characteristics, and full adverse event breakdown were not reported in the abstract and require the full text for confirmation.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42740438/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42740438%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42740438/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42740438/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42740438/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42740438/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42740438/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42740438/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42740438%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42740438%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42740438/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42740438/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42740438/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42740438/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42740438/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42740438/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42740438/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42740438/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42740438/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42740438/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42740438/#substances) Title & authors Abstract Similar articles Publication types MeSH terms Substances Randomized Controlled Trial Gut Liver Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gut+Liver%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gut+Liver%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42740438/) . 2026 Sep 15;20(5):756-764. doi: 10.5009/gnl250435. # Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant _Helicobacter pylori_ Infection: A Multicenter Randomized Controlled Trial [Myeongseok Koh](https://pubmed.ncbi.nlm.nih.gov/?term=Koh+M&cauthor_id=42740438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-1 "Department of Internal Medicine, Dong-A University Hospital, Busan, Korea."), [Cheol Woong Choi](https://pubmed.ncbi.nlm.nih.gov/?term=Choi+CW&cauthor_id=42740438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-2 "Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea."), [Dae Gon Ryu](https://pubmed.ncbi.nlm.nih.gov/?term=Ryu+DG&cauthor_id=42740438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-2 "Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea."), [Seung Jung Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+SJ&cauthor_id=42740438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-3 "Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea."), [Sung Eun Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+SE&cauthor_id=42740438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-4 "Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea."), [Kyoungwon Jung](https://pubmed.ncbi.nlm.nih.gov/?term=Jung+K&cauthor_id=42740438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-4 "Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea."), [Bong Eun Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+BE&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Moon Won Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+MW&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Dong Chan Joo](https://pubmed.ncbi.nlm.nih.gov/?term=Joo+DC&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Jin Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+J&cauthor_id=42740438)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-6 "Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea."), [Ra Ri Cha](https://pubmed.ncbi.nlm.nih.gov/?term=Cha+RR&cauthor_id=42740438)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-7 "Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea."), [Sam Ryong Jee](https://pubmed.ncbi.nlm.nih.gov/?term=Jee+SR&cauthor_id=42740438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#full-view-affiliation-3 "Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.") Affiliations Expand ### Affiliations * 1 Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. * 2 Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea. * 3 Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. * 4 Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. * 5 Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. * 6 Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. * 7 Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea. * PMID: **42740438** * DOI: [ 10.5009/gnl250435 ](https://doi.org/10.5009/gnl250435) Item in Clipboard Randomized Controlled Trial # Fourteen-Day Amoxicillin- or Tetracycline-Containing Bismuth Quadruple Therapy versus 14-Day Metronidazole-Based Triple Therapy as the Treatment for Clarithromycin-Resistant _Helicobacter pylori_ Infection: A Multicenter Randomized Controlled Trial Myeongseok Koh et al. Gut Liver. 2026. Show details Display options Display options Format Abstract PubMed PMID Gut Liver Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gut+Liver%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Gut+Liver%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42740438/) . 2026 Sep 15;20(5):756-764. doi: 10.5009/gnl250435. ### Authors [Myeongseok Koh](https://pubmed.ncbi.nlm.nih.gov/?term=Koh+M&cauthor_id=42740438)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-1 "Department of Internal Medicine, Dong-A University Hospital, Busan, Korea."), [Cheol Woong Choi](https://pubmed.ncbi.nlm.nih.gov/?term=Choi+CW&cauthor_id=42740438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-2 "Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea."), [Dae Gon Ryu](https://pubmed.ncbi.nlm.nih.gov/?term=Ryu+DG&cauthor_id=42740438)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-2 "Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea."), [Seung Jung Yu](https://pubmed.ncbi.nlm.nih.gov/?term=Yu+SJ&cauthor_id=42740438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-3 "Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea."), [Sung Eun Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+SE&cauthor_id=42740438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-4 "Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea."), [Kyoungwon Jung](https://pubmed.ncbi.nlm.nih.gov/?term=Jung+K&cauthor_id=42740438)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-4 "Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea."), [Bong Eun Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+BE&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Moon Won Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+MW&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Dong Chan Joo](https://pubmed.ncbi.nlm.nih.gov/?term=Joo+DC&cauthor_id=42740438)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-5 "Department of Internal Medicine, Pusan National University Hospital, Busan, Korea."), [Jin Lee](https://pubmed.ncbi.nlm.nih.gov/?term=Lee+J&cauthor_id=42740438)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-6 "Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea."), [Ra Ri Cha](https://pubmed.ncbi.nlm.nih.gov/?term=Cha+RR&cauthor_id=42740438)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-7 "Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea."), [Sam Ryong Jee](https://pubmed.ncbi.nlm.nih.gov/?term=Jee+SR&cauthor_id=42740438)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42740438/#short-view-affiliation-3 "Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.") ### Affiliations * 1 Department of Internal Medicine, Dong-A University Hospital, Busan, Korea. * 2 Department of Internal Medicine, Medical Research Institute, Pusan National University School of Medicine and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea. * 3 Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. * 4 Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. * 5 Department of Internal Medicine, Pusan National University Hospital, Busan, Korea. * 6 Department of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea. * 7 Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea. * PMID: **42740438** * DOI: [ 10.5009/gnl250435 ](https://doi.org/10.5009/gnl250435) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Background/aims:** Combination therapy comprising a proton pump inhibitor (PPI), amoxicillin, and metronidazole (PAM) is used to treat clarithromycin-resistant _Helicobacter pylori_ in the Republic of Korea, but eradication rates are decreasing due to an increasing incidence of clarithromycin resistance. We compared PAM, bismuth compounds plus PAM (PAM-B), and the combination of PPI, bismuth compounds, metronidazole, and tetracycline (PBMT) to determine whether PAM-B can achieve an eradication rate higher than that of PAM and comparable to that of PBMT. **Methods:** This prospective multicenter study enrolled patients with clarithromycin-resistant _H. pylori_ infections in the Busan and Gyeongsangnam-do of the Republic of Korea between December 2022 and February 2024. **Results:** In the intention-to-treat (ITT) analysis, the eradication rate was significantly lower in the PAM group (68.2%) than in the PAM-B group (84.8%, p=0.024), whereas the difference from the PBMT group (81.8%) was not significant (p=0.070). The rate remained lowest in the PAM group (75.4%) in the per-protocol (PP) analysis (PAM-B, 96.5%, p=0.001; PBMT, 94.6%, p=0.004). Eradication rates were comparable between the PAM-B and PBMT groups in both the ITT (p=0.640) and PP analyses (p=0.633). Nausea and vomiting were significantly less frequent in the PAM-B group than in the PBMT group (6.8% vs 25.0%; p=0.007). Severe adverse events were rare, and all symptoms resolved after treatment discontinuation. **Conclusions:** PAM-B yielded eradication rates higher than those of PAM and comparable to those of PBMT, with no significant increase in the incidence of adverse events, suggesting the potential of PAM-B as a first-line treatment for clarithromycin-resistant _H. pylori_ infection. Further large-scale studies are needed to validate these results. Registered retrospectively with the Clinical Research Information Service (CRIS; KCT0012265). **Keywords:** Antibiotic resistance; Bismuth; Clarithromycin; Eradication; Helicobacter pylori. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. ](https://pubmed.ncbi.nlm.nih.gov/28807915/) Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.Tsay FW, et al.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00140-17. doi: 10.1128/AAC.00140-17. Print 2017 Nov.Antimicrob Agents Chemother. 2017.PMID: 28807915Free PMC article.Clinical Trial. * [ Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China. ](https://pubmed.ncbi.nlm.nih.gov/29914954/) Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H, Zeng Z, Chen S, Liu D, Lv N; the Chinese Study Group on Helicobacter pylori, Chinese Society of Gastroenterology.Xie Y, et al.Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00432-18. doi: 10.1128/AAC.00432-18. Print 2018 Sep.Antimicrob Agents Chemother. 2018.PMID: 29914954Free PMC article.Clinical Trial. * [ Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant _Helicobacter pylori_ Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens. ](https://pubmed.ncbi.nlm.nih.gov/38712395/) Lim CH, Oh JH.Lim CH, et al.Gut Liver. 2024 Nov 15;18(6):970-976. doi: 10.5009/gnl230453. Epub 2024 May 7.Gut Liver. 2024.PMID: 38712395Free PMC article.Clinical Trial. * [ Optimum duration of regimens for Helicobacter pylori eradication. ](https://pubmed.ncbi.nlm.nih.gov/24338763/) Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Od
## Related Clinical Research

- [Enhancing Medication Safety During Pregnancy: Research Insights](https://medichelpline.com/clinical-feed/plos-medicine-0-towards-improving-the-safety-of-medication-use-in-pregnancy.md)
- [Delabelling Pediatric Amoxicillin Allergy Using Direct Oral Challenge in Northwestern Ontario](https://medichelpline.com/clinical-feed/pubmed-42629506.md) (DOI: 10.1007/s00431-026-07169-x)
- [Clavacillin (Amoxicillin And Clavulanate Potassium) Powder, For Suspension](https://medichelpline.com/clinical-feed/dailymed-updates-1-clavacillin-amoxicillin-and-clavulanate-potassium-powder-for-suspension-dechra-veterinary-products-llc-.md)
- [Antibiotic residues and risk assessment in Dunga wetland and drinking water, Kisumu, Kenya](https://medichelpline.com/clinical-feed/pubmed-43055995.md) (DOI: 10.1007/s10661-026-16164-6)
- [Spreading depolarization alters distant cortical connectivity after focal injury](https://medichelpline.com/clinical-feed/plos-one-10-spreading-depolarization-drives-distant-connectivity-changes-in-the-focally.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.